Cite
MLA Citation
Mohammed Milhem et al.. “O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab.” Journal for immunotherapy of cancer, vol. 8, n.d., pp. A2–A3. http://access.bl.uk/ark:/81055/vdc_100137785043.0x000001